Upstream Bio (UPB) Other Non-Current Liabilities (2023)

Upstream Bio's (UPB) quarterly Other Non-Current Liabilities came in at $2.9 million in Q4 2023.

Upstream Bio (UPB) Other Non-Current Liabilities (2023) Analysis & Trends

Upstream Bio's Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $2.9 million for Q4 2023.

On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $2.9 million in Q4 2023; TTM through Dec 2023 was $2.9 million, a N/A change from a year earlier, with the FY2023 full-year figure at $2.9 million, changed N/A from the prior year.
Other Non-Current Liabilities held at $2.9 million in Q4 2023 per UPB's latest filing.
Across five years, Other Non-Current Liabilities topped out at $2.9 million in Q4 2023 and bottomed at $2.9 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Upstream Bio	347.73 Mn	347.73 Mn	-3.94 Mn

Download Data

Date	Value
Dec 31, 2023	2.87 Mn